CERo Therapeutics presenting poster on innovative cancer therapy utilizing patient's immune system

From GlobeNewswire: 2025-04-25 08:15:00

CERo Therapeutics Holdings, Inc. will present a poster at the ASCO 2025 Annual Meeting, titled “First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-L in acute myeloid leukemia (CertainT-1).” CEO Chris Ehrlich looks forward to discussing this innovative study protocol, aiming to revolutionize cancer therapy by utilizing the patient’s immune system and a novel target. The Company is initiating a Phase 1/1b study to evaluate CER-1236 in patients with acute myeloid leukemia, focusing on safety and preliminary efficacy. CERo’s unique approach to T cell engineering is designed to optimize cancer therapy by engaging the body’s full immune repertoire.



Read more at GlobeNewswire: CERo Therapeutics Holdings, Inc. to Present Poster on Lead